Subclinical Tuberculosis Disease-A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology.
TB prevalence surveys
TB screening
chest X-ray screening
subclinical TB
symptom screening
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
received:
19
05
2020
pubmed:
17
9
2020
medline:
10
8
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
While it is known that a substantial proportion of individuals with tuberculosis disease (TB) present subclinically, usually defined as bacteriologically-confirmed but negative on symptom screening, considerable knowledge gaps remain. Our aim was to review data from TB prevalence population surveys and generate a consistent definition and framework for subclinical TB, enabling us to estimate the proportion of TB that is subclinical, explore associations with overall burden and program indicators, and evaluate the performance of screening strategies. We extracted data from all publicly available prevalence surveys conducted since 1990. Between 36.1% and 79.7% (median, 50.4%) of prevalent bacteriologically confirmed TB was subclinical. No association was found between prevalence of subclinical and all bacteriologically confirmed TB, patient diagnostic rate, or country-level HIV prevalence (P values, .32, .4, and .34, respectively). Chest Xray detected 89% (range, 73%-98%) of bacteriologically confirmed TB, highlighting the potential of optimizing current TB case-finding policies.
Identifiants
pubmed: 32936877
pii: 5906549
doi: 10.1093/cid/ciaa1402
pmc: PMC8326537
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e830-e841Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MC_UU_00004/04
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Sci Rep. 2019 Oct 18;9(1):15000
pubmed: 31628424
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
Trop Med Int Health. 2015 Sep;20(9):1128-1145
pubmed: 25943163
PLoS Pathog. 2013;9(7):e1003468
pubmed: 23853590
Lancet Respir Med. 2019 Mar;7(3):199-201
pubmed: 30823971
Tuberculosis (Edinb). 2019 Jul;117:31-35
pubmed: 31378265
Lancet. 1999 Feb 6;353(9151):444-9
pubmed: 9989714
Nat Med. 2018 Nov;24(11):1708-1715
pubmed: 30397355
N Engl J Med. 2019 Oct 3;381(14):1347-1357
pubmed: 31577876
Bull World Health Organ. 1967;37(6):819-74
pubmed: 5301821
Clin Chest Med. 2019 Dec;40(4):829-837
pubmed: 31731987
Tubercle. 1981 Sep;62(3):155-67
pubmed: 7032018
Clin Infect Dis. 2018 Nov 13;67(11):1653-1659
pubmed: 29697779
Bull World Health Organ. 2010 Apr;88(4):273-80
pubmed: 20431791
PLoS Med. 2016 Sep 06;13(9):e1002119
pubmed: 27598345
Lancet. 2014 Jun 14;383(9934):2057-2064
pubmed: 24650955
Lancet Infect Dis. 2019 Nov;19(11):1170-1171
pubmed: 31657778
Lancet Infect Dis. 2018 Jan;18(1):76-84
pubmed: 29198911
Nat Rev Microbiol. 2009 Dec;7(12):845-55
pubmed: 19855401
Int J Tuberc Lung Dis. 2006 Aug;10(8):876-82
pubmed: 16898372
Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14
pubmed: 20049645
Lancet Respir Med. 2018 Apr;6(4):244-246
pubmed: 29595504